Advertisement

Topics

Latest "Biomarker discovery Driving technologies" News Stories

17:14 EDT 1st May 2016 | BioPortfolio

Here are the most relevant search results for "Biomarker discovery Driving technologies" found in our extensive news archives from over 250 global news sources.

More Information about Biomarker discovery Driving technologies on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Biomarker discovery Driving technologies for you to read. Along with our medical data and news we also list Biomarker discovery Driving technologies Clinical Trials, which are updated daily. BioPortfolio also has a large database of Biomarker discovery Driving technologies Companies for you to search.

Showing "Biomarker discovery Driving technologies" News Articles 1–25 of 12,000+

Relevant

Oxford BioDynamics expands biomarker discovery programme for ALS

Oxford BioDynamics is expanding its biomarker discovery programme for the development of companion diagnostic tests for Amyotrophic Lateral Sclerosis (ALS), using its EpiSwitch technology


Biomarker Discovery Offers New Hope for TB Vaccine

A team of scientists led by Oxford University have made a discovery that could improve our chances of developing an effective vaccine against Tuberculosis. The researchers have identified new biomarkers for Tuberculosis (TB) which have shown for the first time why immunity from the widely used Bacillus Calmette-Guérin (BCG) vaccine is so variable. The biomarkers will also provide valuable clues ...

Biomarkers of Cancer

Biomarkers of Cancer Larry H. Bernstein, MD, FCAP, Curator LPBI   Biomarker Discovery Gets a Fix on Cancer GEN Feb 1, 2016 (Vol. 36, No. 3)   http://www.genengnews.com/gen-articles/biomarker-discovery-gets-a-fix-on-cancer/5674/ Just Because Cancer Is a Moving Target—Emerging Here, Eluding Treatment There—Doesn’t Mean It Can’t Be Tracked Kathy Liszewsky http://www.genengnews.com/Med...


Epistem announces collaboration with Sanofi Aventis

Epistem plc, the UK biotechnology and personalised medicine company today announced a collaboration with sanofi-aventis U.S. Inc. relating to the use of Epistem's proprietary biomarker gene expression profiling and immunohistochemistry technologies. Under the terms of the agreement sanofi-aventis has entered into a 3 year collaboration with Epistem to provide discovery through to clinical biomarke...

Biomarker discovery offers hope for new TB vaccine

A team of scientists led by Oxford University have made a discovery that could improve our chances of developing an effective vaccine against Tuberculosis.

Smarter driving, using your phone

Mobile-based telematics — apps and hardware that measure driving behaviors — may be the future of safer roads. Increasingly, people are using these technologies to improve their own driving habits, while insurance companies use the data to offer rewards and discounts to safe drivers. One of the most prominent companies — and one of the […]

Denovo Biomarkers: Robert Little. Providing a novel biomarker solution to personalize drug development

Robert Little, the Chief Business Officer of Denovo Biomarkers reveals to Fintan Walton the use of its industry's first platform and algorithm to perform de novo genomic biomarker discovery retrospectively using archived clinical samples.

Researchers identify biomarker of early lung cancer that may increase survival

(American Thoracic Society) Researchers in Taiwan have identified a biomarker that detects the most common lung cancer in its earliest stage. The discovery could one day change how long lung cancer patients live.

Horizons of drug discovery

Horizons of drug discovery Larry H. Bernstein, MD., FCAP, Curator LPBI   Phenotypic and Biomarker-based Drug Discovery NY Acad Sci.    http://www.nyas.org/Publications/Ebriefings/Detail.aspx Organizers: Michael Foley (Tri-Institutional Therapeutics Discovery Institute), Ralph Garippa (Memorial Sloan-Kettering Cancer Center), David Mark (F. Hoffmann-La Roche), Lorenz Mayr (Astra Zeneca), Joh...

GCxGC-MS Validated for Metabolomics Profiling, Biomarker Discovery

MIQE compliance in expression profiling and clinical biomarker discovery

Metabolomics in rheumatic diseases: desperately seeking biomarkers

In the setting of inflammatory diseases, metabolic profiling has potential applications in diagnosis, monitoring and defining disease pathogenesis. This Review focuses on metabolomic studies in rheumatic diseases, including discussion of state-of-the-art technologies, recent insights into disease mechanisms and treatment targets, and the feasibility of metabolomics for biomarker discovery.

Dr. Suso Platero of Janssen Research & Development Speaking on "Translational Medicine: Using Biomarkers in Clinical Trials" at the Biomarker Conference in San Diego, CA

San Diego, CA, November 08, 2015 --(PR.com)-- R&D spending in biomarkers coupled with increased healthcare expenditure and growing utility of biomarkers for diagnostics is driving the biomarkers market worldwide. Growing at a CAGR of 13.58% from 2015 to 2020, the global biomarkers market is estimated to reach $45.55 billion by 2020. Aiding the growth are new developments in biomarker research...

Research discovers neuroprotective protein in blood is biomarker of Alzheimer's disease

(American Friends of Tel Aviv University) A new discovery by Tel Aviv University researchers takes the medical community a leap forward in the process of effectively screening and diagnosing Alzheimer's disease. The study proposes a new biomarker for cognitive aging and Alzheimer's disease, the levels of which can be easily monitored in routine blood tests.

Volvo, Microsoft HoloLens Partner to Improve Driving Tech

Volvo Cars and Microsoft HoloLens have announced a joint venture to develop next-generation automotive technologies, including autonomous driving and revamping the customer purchasing experience with augmented reality.Read more about Volvo, Microsoft HoloLens Partner to Improve Driving Tech

Quest Diagnostics spins Enterix's biomarker business off into newco Clinical Genomics

Following its acquisition of colorectal cancer testing company Enterix Inc. earlier this year, Quest Diagnostics Inc. has spun off that company's biomarker business into a new firm, Clinical Genomics Technologies Pty. Ltd. Quest holds a 19.9% equity stake in the spin-off, according to regulatory filings.

Interactive Motion Technologies Names CEO and Chairman of the Board

WATERTOWN, MA -- Interactive Motion Technologies Inc. announced Nov. 25 the appointment of Jules M. Fried as CEO and Hermano Igo Krebs, PhD, as chairman of the board of directors, effective immediately. Fried joined Interactive Motion Technologies in a consulting capacity in May 2015. "I am delighted joining Interactive Motion Technologies at this exciting time, when rehabilitation provide...

Clinical Trial Partnerships: Driving Forward New Technologies And Collaborations

Consolidation among contract research organizations (CROs), the emergence of disruptive digital technologies and a continuing emphasis on "patient centricity" and risk-based monitoring (RBM) have featured in the news in the past 12 months.

Dr Sandip Patel to Speak on Biomarkers for Cancer Immunotherapy: Beyond PD-L1

San Diego, CA, November 22, 2015 --(PR.com)-- The Biomarker Conference, organized by MnM Conferences, will be held on 18 - 19 February 2016 in San Diego-CA, USA. At the conference experts from pharma, bio - pharma companies and research institutes ​will be gathering to discuss emerging pathways and breakthroughs in biomarker discovery and successful validation in consort with the regulatory...

CardiNor Signs CV Biomarker Deal With Bioventix

Early-stage Norwegian cardiovascular biomarker developer CardiNor has signed a deal with UK-based sheep monoclonal antibody company Bioventix, which will supply antibodies for use in CardiNor’s project to develop a biomarker to better target patients that should be implanted with Implantable Cardioverter Defibrillators.

Crawford Technologies' New Voiceye Solution Featured on Discovery Channel's NewsWatch Program

Toronto, ON (PRWEB) March 17, 2016 Crawford Technologies announced today that its new Voiceye solution – allowing visually-impaired customers to read printed pages - has been featured on the Discovery’s Channel’s NewsWatch program. NewsWatch is a 30-minute segment airing weekly in more than 2...

Alan Wright, CMO of Roche Diagnostics, to Keynote at Biomarkers Summit 2016

San Diego, CA, February 18, 2016 --(PR.com)-- Alan Wright, Chief Medical Officer of Roche Diagnostics, will give a keynote presentation on “Creating Personalized Diagnostics Ecosystems” at GTCbio’s Biomarkers Summit 2016 to be held on March 21-23, 2016 in San Diego, CA. With a heavy national focus on the bottom line of healthcare, the “what” and “how” of...

Data Bridge Market Research Has Added a New Market Report on "Global Cancer Biomarkers Market – Analysis and Forecast 2012 – 2020"

Dallas, TX, February 23, 2016 --(PR.com)-- Cancer biomarkers are the molecules secreted by a tumor or a specific response of the human body indicating the presence of cancer. The biomarkers enable cancer detection at an early stage and facilitate high-speed noninvasive diagnosis using various genomics and proteomics tools. Cancer biomarkers are used for various applications such as cancer diagnos...

TiGenix spins out drug discovery unit as Arcarios

TiGenix NV (regenerative medicine for cartilage, bone and other connective tissues) has combined the operations of its former TR-therapeutics subsidiary--a discovery company in the field of osteoarthritis based on technologies and IP of the University of Ghent, the Katholieke Universiteit Leuven, and the Center for Drug Design & Discovery--and Therosteon, a 2008 spin-off from the Erasmus Medical C...

CannaPharmaRx's Drug Discovery Platform

​CannaPharmaRx, Inc., announced plans today for the development of its "CannaSyn" drug discovery platform. The CannaSyn technology is a platform for rapid, targeted new molecule discovery and production. According to Mathew Sherwood, Vice President of Product Development at CannaPharmaRx, "CannaSyn is the engine that will drive our targeted drugdiscovery, as well as develop valuable new prod...


Quick Search
Advertisement
 

News Quicklinks